Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Palisade Bio (PALI) over the last 14 years, with Q3 2025 value amounting to $211000.0.

  • Palisade Bio's Other Accumulated Expenses fell 1021.28% to $211000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $211000.0, marking a year-over-year decrease of 1021.28%. This contributed to the annual value of $243000.0 for FY2024, which is 3351.65% up from last year.
  • Per Palisade Bio's latest filing, its Other Accumulated Expenses stood at $211000.0 for Q3 2025, which was down 1021.28% from $314000.0 recorded in Q2 2025.
  • In the past 5 years, Palisade Bio's Other Accumulated Expenses registered a high of $349000.0 during Q2 2024, and its lowest value of $11000.0 during Q2 2022.
  • For the 5-year period, Palisade Bio's Other Accumulated Expenses averaged around $149466.7, with its median value being $178000.0 (2024).
  • Per our database at Business Quant, Palisade Bio's Other Accumulated Expenses tumbled by 8625.0% in 2022 and then soared by 135416.67% in 2024.
  • Palisade Bio's Other Accumulated Expenses (Quarter) stood at $27000.0 in 2021, then soared by 225.93% to $88000.0 in 2022, then surged by 106.82% to $182000.0 in 2023, then skyrocketed by 33.52% to $243000.0 in 2024, then decreased by 13.17% to $211000.0 in 2025.
  • Its Other Accumulated Expenses was $211000.0 in Q3 2025, compared to $314000.0 in Q2 2025 and $225000.0 in Q1 2025.